Cell engineering

BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development

Retrieved on: 
Thursday, May 2, 2024
Process, Microsoft Exchange Server, Genetic engineering, MSC, Exosome, Partnership, Engineering, Therapy, Regenerative medicine, Cell engineering, Mesenchymal stem cell, The Product, BSD, CGMP, Pharmaceutical industry

FREDERICK, Md., May 2, 2024 /PRNewswire-PRWeb/ -- BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.

Key Points: 
  • Together, BSD and RoosterBio deliver an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics.
  • FREDERICK, Md., May 2, 2024 /PRNewswire-PRWeb/ -- BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.
  • "By combining Biosolution Designs' innovative multigenic technologies with our well-established cell therapy products and scalable bioprocess manufacturing platforms, we will accelerate the clinical progression of the next generation of cell and exosome therapeutics."
  • "BSD is at the leading edge of advanced therapy engineering," said Tim Kelly, CEO of RoosterBio.

Mekonos Enters Partnership Agreement with Accelerated Biosciences to Develop and Commercialize Engineered Human Trophoblast Stem Cells (hTSCs) for Biomanufacturing

Retrieved on: 
Thursday, May 2, 2024
Semiconductor, Health, Technology, Health Technology, Nanotechnology, Biotechnology, Immortalised cell line, Cell, GEMS, Gene editing, Partnership, Doctor of Philosophy, B cell, Cuprate superconductor, Cell engineering, Toxicology, Drug discovery, Medicine, Growth, Vaccine

Mekonos, Inc. , a biotech platform company building the future of cell engineering on a chip, today announced it has entered into a partnership agreement with Accelerated Biosciences Corp. (“Accelerated Bio”) to codevelop a powerful, new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.

Key Points: 
  • Mekonos, Inc. , a biotech platform company building the future of cell engineering on a chip, today announced it has entered into a partnership agreement with Accelerated Biosciences Corp. (“Accelerated Bio”) to codevelop a powerful, new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.
  • The hTSC platform is the earliest ethically sourced pluripotent stem cells that are naive, powerful, lively and have high plasticity.
  • These limitations compound and can cause cell functionality compromises and performance issues downstream, given the lack of consistency in engineered cells and inefficient scale-up.
  • Mekonos recognizes there is a better way, and we are rising to the challenge,” Narasimha added.

EditCo Bio, Inc. Unveils Novel Knockout CD4+ T-cell Pools to Transform Cancer and Autoimmune Research

Retrieved on: 
Thursday, April 18, 2024
Health Technology, Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Oncology, General Health, Genetics, Clinical Trials, Biotechnology, Science, Software, Other Science, Research, Health, Cancer, CRISPR, Genetic engineering, Immunotherapy, Gene editing, Cell, Cryopreservation, CSO, Cell engineering, Knockout, TCR, IL2, TNFA

EditCo Bio, Inc., a pioneer at the forefront of genome engineering innovation, today announced the launch of its Knockout CD4+ T-cell Pools .

Key Points: 
  • EditCo Bio, Inc., a pioneer at the forefront of genome engineering innovation, today announced the launch of its Knockout CD4+ T-cell Pools .
  • T-cells, pivotal in the immune response, hold immense promise for elucidating the pathways of various diseases, including cancer and autoimmune conditions.
  • The introduction of Knockout CD4+ T-cell Pools is a strategic extension of EditCo Bio’s comprehensive Engineered Cell portfolio.
  • For more information regarding EditCo Bio’s CD4+ T-cell Pools, visit www.EditCo.bio/contact .

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Retrieved on: 
Tuesday, April 2, 2024
Partnership, Engineering, Patient, DSM-IV codes, Cell engineering, SPL, Cancer, BCMS, Pharmaceutical industry

Under the terms of the agreement, Be Bio obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Be Bio obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.
  • “We are thrilled to support Be Bio’s pioneering efforts in the creation of Engineered B Cell Medicines (BCMs),” said Maher Masoud, President and CEO of MaxCyte.
  • Be Bio is MaxCyte’s 27th clinical/commercial partnership overall, each of which generates pre-commercial milestone revenue, the vast majority of which include sales-based payments.

Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science

Retrieved on: 
Tuesday, April 9, 2024
Cell engineering, Vanderbilt University, Development, Gene editing, Biotechnology, Entrepreneurship, Science, Research, Messenger, Therapy, DRS, Biological engineering, Chemical engineering, Lehigh University, Research fellow, Vaccine

CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.

Key Points: 
  • CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.
  • "We are excited to welcome three talented scientific professionals to Factor," said Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor.
  • "Dr. Garland, who is joined by Associate Scientists, Raven Hinkel and Elizabeth Belcher, has deep translational research expertise in mRNA and cell engineering.
  • The addition of Kyle and his team will enhance Factor's ability to support our strategic partners and accelerate our efforts to translate our technologies to new products."

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs

Retrieved on: 
Tuesday, April 2, 2024
Cell engineering, Immunotherapy, Partnership, Library, Research, DNA, Gene, Acquisition, Society, Wisconsin Alumni Research Foundation, Therapy, Modulus, Safety, Poster, SITC, Cell, WARF, Autoimmunity, Annual general meeting, Vaccine

Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.

Key Points: 
  • Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.
  • In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors.
  • Jason Kelly, CEO and co-founder of Ginkgo Bioworks: "Modulus Therapeutics has built an array of incredible cell therapy assets that we are excited to add into the significant cell therapy capabilities Ginkgo has developed to date.
  • Ginkgo expects Modulus' cell therapy assets to help Ginkgo continue to strengthen its CAR-T research & development offerings.

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
DNA, Pfizer, Merck, Cell engineering, Forecasting, Form 10-K, Growth, Novo Nordisk, Cell, Annual report, Feedback, GAAP, Boehringer Ingelheim, Ecosystem, K-12, Video game

BOSTON, Feb. 29, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2023. The update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com.

Key Points: 
  • The update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com .
  • "2023 was a breakout year for Ginkgo," said Jason Kelly, co-founder and CEO of Ginkgo.
  • As of December 31, 2023 Ginkgo has approximately $2.4 billion in aggregate revenue potential from downstream milestone payments alone in addition to royalties.
  • There was no material downstream value share revenue received in the fourth quarter of 2023.

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Retrieved on: 
Tuesday, January 30, 2024
Partnership, Cell engineering, LBL, Orphan drug, Expert, NK, Patient, Transfection, Adolescence, NCT, MBA, Food, Cancer, CD7, Doctor of Philosophy, SPL, Pharmaceutical industry

Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • Wugen is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.
  • The company’s investigational cell therapies originate from healthy donors and are further engineered to enhance their function of eliminating cancer cells.
  • Wugen is MaxCyte’s 26th clinical/commercial partnership overall, each of which generates pre-commercial milestone revenue, the vast majority of which includes sales-based payments.

Phytolon and Ginkgo Bioworks Successfully Achieve First Milestone to Produce Vibrant Natural Food Colors via Two Producing Strains

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Cell engineering, Senior, DNA, Food, Biotechnology, Commercialization, Food industry

Ginkgo and Phytolon's partnership, which began in February 2022, aims to produce vibrant betalain pigments spanning the entire yellow-to-purple spectrum using cell engineering.

Key Points: 
  • Ginkgo and Phytolon's partnership, which began in February 2022, aims to produce vibrant betalain pigments spanning the entire yellow-to-purple spectrum using cell engineering.
  • By leveraging Ginkgo Natural Product Services , Phytolon has significantly improved the efficiency of its yeast strains to generate these vibrant, sustainable colors and offer cost-efficient replacements to artificial dyes.
  • By partnering with Ginkgo, Phytolon is in a strong position to scale their robust array of food colorants for the global market.
  • Ginkgo and Phytolon will continue to work together under their existing agreement toward achieving additional milestones that further increase production efficiency.

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Retrieved on: 
Tuesday, January 23, 2024
ASX, Neoplasm, Patient, Precision, Partnership, Imugene, Cancer, Workflow, GMP, CD19, IMU, Cell engineering, SPL, Bone marrow, Transfection, Immune system, Pharmaceutical industry

Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
  • Imugene, which has offices in the United States and Australia, is focused on developing transformative cancer medicines to improve patients’ lives.
  • Imugene is MaxCyte’s 25th SPL overall, which generates pre-commercial milestone revenue, the vast majority of which includes post-commercial revenue.